Now, many thousands more people are contributing DNA samples for a wide array of follow-on studies designed to turn the project’s findings to practical use in health care, genetics and biological research.
Researchers and doctors have opened a new era of “personalized medicine” that seeks to tailor therapies to patients based on their unique genetic makeups and medical histories.
According to the National Cancer Institute, the days are passing when most cancer tumors were thought to be essentially the same and patients got the same drugs.
“We’re not very good at selecting therapies for individual patients,” Dr. Rick Hockett, the chief medical officer of Affymetrix, a genetics firm in Santa Clara, Calif., told a conference on personalized medicine this month in Washington. “Targeted therapy,” he said, can “improve the benefit-risk ratio for patients.”
For example, Hockett said that heart patients who took the popular anti-clotting drug Plavix had a greatly increased risk of serious problems, including death, if they had two tiny mutations in their genes.